XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Net revenues $ 3,870 $ 4,177 $ 8,227 $ 8,326
Cost of sales 2,107 2,284 4,402 4,577
Gross profit 1,763 1,893 3,826 3,749
Research and development expenses 225 276 446 537
Selling and marketing expenses 597 666 1,210 1,313
General and administrative expenses 264 296 567 589
Intangible assets impairments 120 561 768 1,030
Other assets impairments, restructuring and other items 381 101 502 103
Legal settlements and loss contingencies 13 646 (12) 703
Other income (9) (9) (22) (15)
Operating (loss) income 173 (644) 364 (510)
Financial expenses, net 223 206 448 425
Income (loss) before income taxes (51) (850) (84) (934)
Income taxes (benefit) (104) (179) (163) (170)
Share in (profits) losses of associated companies, net 0 0 0 4
Net income (loss) 53 (671) 78 (768)
Net income (loss) attributable to non-controlling interests (87) 18 (131) 26
Net income (loss) attributable to Teva $ 140 $ (689) $ 209 $ (794)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.13 $ (0.63) $ 0.19 $ (0.73)
Diluted $ 0.13 $ (0.63) $ 0.19 $ (0.73)
Weighted average number of shares (in millions):        
Basic 1,096 1,092 1,095 1,091
Diluted 1,100 1,092 1,098 1,091